文献速递流行病学与生物统计真实世界研究与卫生经济

癌症治疗延迟与死亡率:系统综述与荟萃分析

Mortality due to cancer treatment delay: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2020-11-04

结果显示17种适应症中13种延迟与死亡率增加显著相关,手术、系统治疗和放疗均可见此关联。

要点

  • 每延迟四周,手术死亡率风险增加,如结肠切除术HR 1.06、乳腺手术HR 1.08。
  • 系统治疗延迟的风险比范围1.01-1.28,因适应症而异。
  • 头颈癌根治性放疗每延迟四周HR 1.09,宫颈癌辅助放疗HR 1.23。

核心结论

  • 癌症治疗延迟在全球卫生系统中普遍存在,每四周延迟与手术、系统治疗和放疗适应症的死亡率增加相关。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline 2000年1月1日至2020年4月10日发表的文献。
  • 纳入膀胱、乳腺、结肠、直肠、肺、宫颈和头颈癌的手术、系统治疗或放疗的治愈性、新辅助和辅助适应症研究。

主要发现

  • 17种适应症中13种延迟与死亡率增加显著相关(P<0.05)。
  • 手术每四周延迟的死亡风险比为1.06-1.08,如结肠切除术1.06(95%CI 1.01-1.12)、乳腺手术1.08(95%CI 1.03-1.13)。
  • 系统治疗的风险比范围为1.01-1.28。
  • 头颈癌根治性放疗HR 1.09(95%CI 1.05-1.14),乳腺癌保乳术后辅助放疗HR 0.98(95%CI 0.88-1.09),宫颈癌辅助放疗HR 1.23(95%CI 1.00-1.50)。

关键数值与推荐

  • 每四周延迟对总生存的风险比采用对数线性假设,合并效应使用DerSimonian and Laird随机效应模型估计。

临床怎么用

  • 治疗延迟对死亡率的影响可量化,用于优先排序和建模。
  • 政策应聚焦于最小化系统层面的癌症治疗启动延迟,以改善人群生存结局。

局限性

  • 五种放疗适应症和宫颈癌手术未找到高有效性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the association of cancer treatment delay and mortality for each four week increase in delay to inform cancer treatment pathways. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Published studies in Medline from 1 January 2000 to 10 April 2020. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Curative, neoadjuvant, and adjuvant indications for surgery, systemic treatment, or radiotherapy for cancers of the bladder, breast, colon, rectum, lung, cervix, and head and neck were included. The main outcome measure was the hazard ratio for overall survival for each four week delay for each indication. Delay was measured from diagnosis to first treatment, or from the completion of one treatment to the start of the next. The primary analysis only included high validity studies controlling for major prognostic factors. Hazard ratios were assumed to be log linear in relation to overall survival and were converted to an effect for each four week delay. Pooled effects were estimated using DerSimonian and Laird random effect models. RESULTS: The review included 34 studies for 17 indications (n=1 272 681 patients). No high validity data were found for five of the radiotherapy indications or for cervical cancer surgery. The association between delay and increased mortality was significant (P<0.05) for 13 of 17 indications. Surgery findings were consistent, with a mortality risk for each four week delay of 1.06-1.08 (eg, colectomy 1.06, 95% confidence interval 1.01 to 1.12; breast surgery 1.08, 1.03 to 1.13). Estimates for systemic treatment varied (hazard ratio range 1.01-1.28). Radiotherapy estimates were for radical radiotherapy for head and neck cancer (hazard ratio 1.09, 95% confidence interval 1.05 to 1.14), adjuvant radiotherapy after breast conserving surgery (0.98, 0.88 to 1.09), and cervix cancer adjuvant radiotherapy (1.23, 1.00 to 1.50). A sensitivity analysis of studies that had been excluded because of lack of information on comorbidities or functional status did not change the findings. CONCLUSIONS: Cancer treatment delay is a problem in health systems worldwide. The impact of delay on mortality can now be quantified for prioritisation and modelling. Even a four week delay of cancer treatment is associated with increased mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers. Policies focused on minimising system level delays to cancer treatment initiation could improve population level survival outcomes.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020. PMID: 33148535. doi:10.1136/bmj.m4087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。